A first-in-human clinical trial is now testing an idea that, until recently, belonged mostly to animal studies and aging research: instead of replacing a damaged nerve cell, can medicine push that cell toward a younger biological state and recover some of the function it has lost?
Life Biosciences is attempting to answer that question with ER-100, an experimental gene therapy for optic neuropathies. The treatment uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4, collectively called OSK, to alter patterns of gene regulation in retinal cells. The company announced on June 9 that the first participant had been dosed in its Phase 1 trial.
That is a significant step. It is not proof that blindness has been cured, that an eye has been regenerated, or that human aging can now be reversed.
The distinction matters because the underlying science is already unusual enough without exaggeration.
What ER-100 is actually trying to repair.
Vision depends on more than the optical components at the front of the eye. Retinal ganglion cells, or RGCs, collect visual information from the retina and send it toward the brain through their axons, which form the optic nerve. In diseases such as open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy, or NAION, those neurons and their axons can be damaged or lost.
Adult mammalian retinal ganglion cells have very limited natural regenerative capacity. That is the relevant biological problem. It is inaccurate to describe the entire eye as “the only organ in the body that cannot regenerate.” Different tissues within the eye have very different repair capacities. The central-nervous-system components of vision, including retinal ganglion cells and the optic nerve, are the harder problem.
ER-100 is aimed at that problem.
The therapy uses a modified adeno-associated virus, or AAV, to deliver genes encoding OCT4, SOX2 and KLF4. These proteins are transcription factors: they help determine which genes are active and how strongly they are expressed.
This is gene therapy, but it is not gene editing in the familiar cut-and-rewrite sense. ER-100 is intended to modify the epigenetic state of existing cells rather than change their underlying DNA sequence.
The Yamanaka factors, used partially.
OCT4, SOX2 and KLF4 are three members of the group commonly known as the Yamanaka factors. In classic cellular reprogramming experiments, Yamanaka factors can push mature cells back toward an induced pluripotent stem-cell state, effectively erasing much of the cell's specialized identity.
That is not what ER-100 is intended to do.
The strategy is called partial epigenetic reprogramming. The goal is to expose cells to a controlled subset of reprogramming factors strongly enough to alter age- or injury-associated regulatory patterns, but not so far that the cells lose their identity.
That distinction is central to the entire approach. A retinal ganglion cell is useful because it is a retinal ganglion cell. Rejuvenating it would be valuable only if it remains the right kind of neuron, in the right place, performing the right job.
Nature Biotechnology described ER-100 in February as a modified-AAV gene therapy delivering OCT4, SOX2 and KLF4 under controlled expression, with the goal of restoring more youthful methylation patterns and cellular function.
What the monkey studies actually showed.
Some of the excitement around ER-100 comes from nonhuman-primate studies using a model of NAION, an optic neuropathy associated with ischemic injury to the optic nerve.
The viral shorthand is that researchers “regenerated an eyeball” or “restored sight to blind monkeys.” Neither description is precise.
Life Biosciences reported that ER-100 significantly reduced deficits in pattern electroretinogram, or pERG, measurements and in optic-nerve axon-density measures when given in both prevention and rescue paradigms in nonhuman primates. Immunohistochemistry also confirmed expression of the three transcription factors in targeted retinal regions.
A pERG is an electrophysiological measurement associated with retinal ganglion-cell function. Improvement in that signal is meaningful evidence that the affected visual pathway is functioning better at the cellular level.
It is not the same thing as demonstrating restoration of normal human-like sight through a behavioral vision test.
That does not make the primate data unimportant. Quite the opposite. Improvement in retinal ganglion-cell function and preservation of optic-nerve structure in a primate model are exactly the kind of findings that can justify cautious movement into human testing. But the evidence should be described at the resolution at which it actually exists.
Animal efficacy is a reason to test a therapy in humans. It is not human efficacy.
What the FDA did, and did not, authorize.
ER-100 has not been approved for general medical use.
The FDA cleared Life Biosciences' Investigational New Drug application. That clearance allows the company to test ER-100 in humans under a defined clinical protocol. It does not establish that the therapy works, and it does not authorize routine clinical use.
The current study, ClinicalTrials.gov identifier NCT07290244, is a Phase 1 trial in adults with open-angle glaucoma or NAION. The registry lists the study as recruiting, with a target enrollment of 18 participants and a start date of March 2, 2026.
The primary objective is safety and tolerability. Because the participants have optic neuropathy rather than being healthy volunteers, the study also includes visual-function endpoints that may provide early efficacy signals.
That point should remain in the foreground. Early human trials are not victory laps. They are where researchers find out whether a therapy that looked promising in preclinical models behaves acceptably in actual patients.
Why the eye is a logical place to start.
The eye is not biologically simple, but it has several features that make it an attractive proving ground for advanced therapies. It is anatomically accessible. Treatments can be delivered locally rather than exposing the entire body. The retina and optic nerve can be examined repeatedly with high-resolution imaging and electrophysiological tests.
Ophthalmology has therefore become an important proving ground for gene therapy more broadly.
ER-100 adds a different question to that history. Instead of supplying a replacement copy of a defective gene for a specific inherited disorder, it attempts to change the regulatory state of cells damaged by aging or injury.
If that works, even partially, it represents a different therapeutic logic.
The target is not a single mutation. The target is the cell's biological state.
That claim is much bigger than this trial.
Partial epigenetic reprogramming has attracted enormous interest because it raises the possibility that some features of cellular aging may be reversible. If older or injured cells retain enough underlying regulatory information to recover a younger pattern of function, medicine may someday be able to restore some damaged tissue without replacing it.
That is an extraordinary possibility.
It remains a possibility.
ER-100 is being tested in a small Phase 1 eye-disease trial. Even a positive result would not establish that whole organs can be rejuvenated, that aging can be broadly reversed in humans, or that the same method will work safely in the brain, heart, liver, muscle or other tissues.
Different tissues present different delivery problems, cell populations, safety constraints and consequences of error. An intervention that can be localized inside one eye is not automatically transferable to the entire body.
The first useful question is therefore much narrower: can controlled OSK expression be delivered safely to human retinal cells in patients with optic neuropathy?
Only after that comes the next question: is there credible evidence of preserved or improved visual function?
What would count as a real signal?
Because the Phase 1 study is small and primarily designed around safety, expectations need to be calibrated carefully.
A meaningful early signal would not require a miracle. Investigators will look for patterns across clinical measurements of vision, retinal and optic-nerve structure, electrophysiology, dose, timing and adverse events.
The strongest future case for efficacy would require convergence: objective functional measurements improving in a clinically meaningful way, structural or physiological evidence consistent with that change, durability over time, and eventually confirmation in larger controlled trials.
A single striking patient would not settle the question. An imaging change without functional benefit would raise different questions than a functional change without a plausible biological correlate.
The therapy's own premise makes this especially important. “Rejuvenation” is a powerful word. It can refer to a molecular change, a shift in gene-expression patterns, improved cellular function, preserved tissue, or meaningful recovery in a patient. Those are not interchangeable outcomes.
The serious story is already remarkable without miracle language. ER-100 is testing whether damaged human retinal neurons can be pushed toward a younger functional state without being converted into stem cells or losing their identity. Preclinical primate data justify the experiment; they do not establish the result in humans. FDA IND clearance authorizes the test; it does not approve the therapy. The next milestone is not “age reversal.” It is a clean safety signal and, if the biology cooperates, the first credible evidence that partial epigenetic reprogramming can improve function in human optic neuropathy.
The experiment has begun.
If ER-100 fails, the trial will still produce information about one of regenerative medicine's most ambitious ideas. If it proves tolerable but ineffective, researchers will learn something important about the gap between epigenetic change and useful tissue recovery. If it produces reproducible functional benefit, the implications for optic neuropathy would be substantial and the implications for partial cellular reprogramming would become much harder to dismiss.
For now, the most scientifically honest description is also the most interesting one:
Researchers are testing whether damaged human neurons can be pushed toward a younger functional state without erasing what those neurons are.
The first human experiment is underway.